BobcatBio
- Biotech or pharma, therapeutic R&D
BobcatBio is a clinical-stage biotech that is developing our first-in-class, autologous M1-amplified macrophage therapy – RB-1355 – that will completely redefine how we treat both solid tumors and lymphomas. RB-1355 orchestrates a precise, personalized, highly potent, multi-pronged tumoricidal immune response consisting of neoantigen-directed polyclonal T cell and antibodies that achieve both local and systemic tumor elimination. RB-1355 is (i) administered without toxic pre-conditioning (lymphodepletion) and (ii) cryopreserved – supporting outpatient use and enabling multiple administrations from a single apheresis. Moreover, RB-1355 is active independent of the presence of actionable mutations or pre-existing specific antigen expression, offering maximum utility across all solid tumor types and lymphomas. In our first in human Phase 1 NHL study, we have impressive results, including a Complete Response. Solid tumor clinical study in 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}